Physical Activity Behavior Change for Older Adults After Dysvascular Amputation

Overview

This pilot study will use mobile-health technology to deliver an intervention designed for lasting physical activity behavior change. The study will assess the feasibility of using the Physical Activity Behavior Change(PABC) intervention for Veterans with lower limb amputation. This intervention will be delivered using wrist-worn wearable activity sensors and a home-based tablet computer to allow real-time physical activity feedback and video interface between the participants and the therapist.

Full Title of Study: “Physical Activity Behavior Change for Older Veterans After Dysvascular Amputation”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: February 22, 2019

Detailed Description

This pilot study will assess the feasibility of using the Physical Activity Behavior Change(PABC) intervention for Veterans with dysvascular lower limb amputation. In addition, preliminary efficacy of the PABC intervention will be assessed using a two-group randomized cross-over design. Testing will occur at baseline (pre-intervention), three months (end of intervention), and six months. The primary aim is to determine feasibility of using the PABC intervention with Veterans who have dysvascular amputation by measuring: 1. participant retention 2. dose goal attainment 3. participant acceptability 4. safety The secondary aim is to preliminary assess efficacy of the PABC intervention by measuring accelerometer-based physical activity and self-report disability effect sizes.

Interventions

  • Behavioral: Physical Activity Behavior Change (PABC)
    • Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
  • Behavioral: Physical Activity Behavior Change (PABC)
    • Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning

Arms, Groups and Cohorts

  • Experimental: Early PABC Intervention
    • GROUP 1 will participate in the Physical Activity Behavior Change (PABC) intervention phase during the first 3 months. GROUP 1 will then participate in a non-exercise control phase during the second 3 months.
  • Experimental: Wait-List Control Intervention
    • GROUP 2 will participate in a non-exercise control phase during the first 3 months. GROUP 2 will then participate in the Physical Activity Behavior Change (PABC) intervention phase in the second 3 months.

Clinical Trial Outcome Measures

Primary Measures

  • Retention Rate
    • Time Frame: 3 months
    • Retention rate will be measured as the percent of participants enrolled in the intervention who complete the intervention.
  • Dose Goal Attainment
    • Time Frame: 3 months
    • Dose goal attainment will be measured as the percent of participants in the intervention phase of the study who meet the dose goal of an average 3% increase in daily steps.
  • Acceptability
    • Time Frame: 3 months
    • Acceptability will be measured using the mean score of the Intrinsic Motivation Inventory – Interest / Enjoyment Subscale. The scores range from 1 to 7, with higher numbers indicating higher acceptability, and a null value of 5.0.
  • Study-Related Adverse Events
    • Time Frame: 3 months
    • Safety will be assessed as differences in rates of study-related adverse events between GROUP 1 and GROUP 2 during the first three months, when GROUP 1 is in the intervention phase and GROUP 2 is in the non-intervention control phase.

Secondary Measures

  • Accelerometer-Based Physical Activity
    • Time Frame: 3 months
    • Physical activity counts will be measured using a waist-mounted accelerometer-based physical activity monitor (Actigraph). The outcome will be average daily physical activity counts.
  • Late Life Function and Disability Scale, Frequency
    • Time Frame: 3 months
    • The Late Life Function and Disability Scale (LLFDSI) will be used to assess the participant-reported disability at each test point. Scores range from 0 to 100, with higher scores indicating higher disability.
  • Accelerometer-Based Physical Activity
    • Time Frame: 6 months
    • Physical activity counts will be measured using a waist-mounted accelerometer-based physical activity monitor (Actigraph). The outcome will be average daily physical activity counts.
  • Late Life Function and Disability Scale, Frequency
    • Time Frame: 6 months
    • The Late Life Function and Disability Scale (LLFDSI) will be used to assess the participant-reported disability at each test point. Scores range from 0 to 100, with higher scores indicating higher disability.
  • Late Life Function and Disability Scale, Limitation
    • Time Frame: 3 months
    • The Late Life Function and Disability Scale (LLFDSI) will be used to assess the participant-reported disability at each test point. Scores range from 0 to 100, with higher scores indicating higher disability.
  • Late Life Function and Disability Scale, Limitation
    • Time Frame: 6 months
    • The Late Life Function and Disability Scale (LLFDSI) will be used to assess the participant-reported disability at each test point. Scores range from 0 to 100, with higher scores indicating higher disability.

Participating in This Clinical Trial

Inclusion Criteria

  • Lower limb amputation 1-5 years prior to enrollment – Type 2 Diabetes Mellitus and/or – Peripheral Artery Disease – Ambulatory using a lower limb prosthesis – English speaking Exclusion Criteria:

  • Traumatic or cancer-related etiology of the lower limb amputation – Unstable heart condition, including: – unstable angina – uncontrolled cardiac dysrhythmia – acute myocarditis – acute pericarditis – Uncontrolled hypertension – Acute systemic infection – Prisoner – Decisionally challenged volunteers – Cancer – Recent cerebral vascular accident (within two years) – lower extremity wound or ulcer that limits ability to ambulate

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • VA Office of Research and Development
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Cory L. Christiansen, PhD, Principal Investigator, Rocky Mountain Regional VA Medical Center, Aurora, CO

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.